Rocío Montes de

3.1k total citations · 1 hit paper
23 papers, 2.2k citations indexed

About

Rocío Montes de is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Rocío Montes de has authored 23 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Molecular Biology, 7 papers in Hematology and 6 papers in Oncology. Recurrent topics in Rocío Montes de's work include Genomics and Chromatin Dynamics (9 papers), Multiple Myeloma Research and Treatments (7 papers) and DNA Repair Mechanisms (4 papers). Rocío Montes de is often cited by papers focused on Genomics and Chromatin Dynamics (9 papers), Multiple Myeloma Research and Treatments (7 papers) and DNA Repair Mechanisms (4 papers). Rocío Montes de collaborates with scholars based in United States, France and United Kingdom. Rocío Montes de's co-authors include Anirban Maitra, David M. Berman, Yutaka Shimada, Philip A. Beachy, D. Neil Watkins, Sunil Karhadkar, James R. Eshleman, Antony R. Parker, Kimberly J. Briggs and Meg R. Gerstenblith and has published in prestigious journals such as Nature, Journal of Biological Chemistry and Nature Genetics.

In The Last Decade

Rocío Montes de

23 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours

2003 1.0k citations David M. Berman, Sunil Karhadkar et al. Nature profile →

Peers

Countries citing papers authored by Rocío Montes de

Since Specialization

Citations

This map shows the geographic impact of Rocío Montes de's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rocío Montes de with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rocío Montes de more than expected).

Fields of papers citing papers by Rocío Montes de

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rocío Montes de. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rocío Montes de. The network helps show where Rocío Montes de may publish in the future.

Co-authorship network of co-authors of Rocío Montes de

This figure shows the co-authorship network connecting the top 25 collaborators of Rocío Montes de. A scholar is included among the top collaborators of Rocío Montes de based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rocío Montes de. Rocío Montes de is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Long-term (≥5 year) remission and survival after treatment with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1 patients (pts) with relapsed/refractory multiple myeloma (RRMM). 2025 ·Journal of Clinical Oncology ·Peter M. Voorhees, Tom Martin, Yi Lin, Adam D. Cohen, Noopur Raje, Myo Htut, Abhinav Deol, Mounzer Agha, Jesús G. Berdeja, Binod Dhakal, Andrzej Jakubowiak, Samir Parekh, Huijun Li, Rocío Montes de, (unknown), Nikoletta Lendvai, Deepu Madduri, Mythili Koneru, Nitin Patel, Sundar Jagannath	1
2	T-Cell Characteristics Impact Response and Resistance to T-Cell–Redirecting Bispecific Antibodies in Multiple Myeloma 2024 ·Clinical Cancer Research ·Christie P.M. Verkleij, (unknown), Marloes E.C. Broekmans, Kristine A. Frerichs, (unknown), Carolien Duetz, (unknown), S. Rubina Baglio, Sheri Skerget, Rocío Montes de, Sonja Zweegman, Raluca Verona, Tuna Mutis, Niels W.C.J. van de Donk	25
3	Identification of hnRNP-A1 as a pharmacodynamic biomarker of type I PRMT inhibition in blood and tumor tissues 2020 ·Scientific Reports ·(unknown), Timothy W. Sikorski, Francesca Zappacosta, Craig D. Wagner, Rocío Montes de, Matthew Szapacs, Roland S. Annan, Yan Liu, Charles F. McHugh, Helai P. Mohammad, Steven P. Piccoli, Caretha L. Creasy	9
4	DREAMM-8: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin with Pomalidomide and Dexamethasone (B-Pd) Vs Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) 2020 ·Blood ·Suzanne Trudel, Randy Davis, Nicole Lewis, Kalpana Bakshi, Bikramjit Chopra, Rocío Montes de, Geraldine Ferron‐Brady, (unknown), Brandon E. Kremer, Ira Gupta, Frank Wu	23
5	DREAMM-5 platform trial: Belantamab mafodotin in combination with novel agents in patients with relapsed/refractory multiple myeloma (RRMM). 2020 ·Journal of Clinical Oncology ·Paul G. Richardson, Swethajit Biswas, Beata Holkova, Nicola Jackson, (unknown), Sofia Paul, Geraldine Ferron‐Brady, Anne Yeakey, (unknown), Rocío Montes de, Christoph M. Ahlers, Marc Ballas, Elaine Paul, Ira Gupta, Joanna Opalińska, Katarina Luptakova	4
6	PF558 THE ANTI-BCMA ANTIBODY-DRUG CONJUGATE GSK2857916 DRIVES IMMUNOGENIC CELL DEATH AND IMMUNE-MEDIATED ANTI-TUMOR RESPONSES, AND IN COMBINATION WITH AN OX40 AGONIST POTENTIATES IN VIVO ACTIVITY 2019 ·HemaSphere ·Rocío Montes de, Sabyasachi Bhattacharya, (unknown), (unknown), (unknown), (unknown), (unknown), Laura Seestaller‐Wehr, Dale A. Cooper, (unknown), Lyuben Tsvetkov, Oliver Kepp, (unknown), Christopher B. Hopson, (unknown), Guido Kroemer, Patrick A. Mayes, Christopher A. Shelton, (unknown), Axel Hoos	14
7	Dreamm-5: Platform Trial Evaluating Belantamab Mafodotin (a BCMA-directed Immuno-conjugate) in Combination with Novel Agents in Relapsed or Refractory Multiple Myeloma (RRMM) 2019 ·Blood ·Paul G. Richardson, Swethajit Biswas, Beata Holkova, Nicola Jackson, (unknown), Weichao Bao, Geraldine Ferron‐Brady, Anne Yeakey, (unknown), Rocío Montes de, (unknown), Sonia Franco, Marc Ballas, Elaine Paul, Katarina Luptakova, Ira Gupta, Joanna Opalinska	7
8	Activation of the p53-MDM4 regulatory axis defines the anti-tumour response to PRMT5 inhibition through its role in regulating cellular splicing 2018 ·Scientific Reports ·(unknown), Wendy A. Kellner, Christine Thompson, Melissa B. Pappalardi, Xiping Zhang, Rocío Montes de, (unknown), Kenneth W. Duncan, Ann Boriack-Sjodin, BaoChau Le, Christina R. Majer, Michael T. McCabe, Chris Carpenter, Neil Johnson, Ryan G. Kruger, Olena Barbash	121
9	Phosphorylation and DNA Binding of HJURP Determine Its Centromeric Recruitment and Function in CenH3CENP-A Loading 2014 ·Cell Reports ·Sebastian Müller, Rocío Montes de, Nicolas Lacoste, Florent Dingli, Damarys Loew, Geneviève Almouzni	66
10	The survival gene MED4 explains low penetrance retinoblastoma in patients with large RB1 deletion 2014 ·Human Molecular Genetics ·Catherine Dehainault, Alexandra Garancher, Laurent Castéra, Nathalie Cassoux, Isabelle Aerts, François Doz, Laurence Desjardins, Livia Lumbroso‐Le Rouic, Rocío Montes de, Geneviève Almouzni, Dominique Stoppa‐Lyonnet, Célio Pouponnot, Marion Gauthier‐Villars, Claude Houdayer	24
11	The histone chaperone HJURP is a new independent prognostic marker for luminal A breast carcinoma 2014 ·Molecular Oncology ·Rocío Montes de, Zachary A. Gurard‐Levin, Frédérique Berger, Haniya Rehman, (unknown), Armelle Corpet, Leanne de Koning, Isabelle Vassias, Natalie A. Twine, Didier Meseure, Fabien Reyal, Alexia Savignoni, Bernard Asselain, Xavier Sastre‐Garau, Geneviève Almouzni	63
12	Barrier-to-Autointegration Factor influences specific histone modifications 2011 ·Nucleus ·Rocío Montes de, Paul R. Andreassen, Katherine L. Wilson	62
13	Cell cycle dynamics of histone variants at the centromere, a model for chromosomal landmarks 2011 ·Current Opinion in Cell Biology ·Ekaterina Boyarchuk, Rocío Montes de, Geneviève Almouzni	30
14	SUMOylation promotes de novo targeting of HP1α to pericentric heterochromatin 2011 ·Nature Genetics ·Christèle Maison, (unknown), Danièle Roche, Rocío Montes de, Aline V. Probst, Isabelle Vassias, Florent Dingli, (unknown), Damarys Loew, Jean‐Pierre Quivy, Geneviève Almouzni	175
15	Barrier-to-Autointegration Factor Proteome Reveals Chromatin-Regulatory Partners 2009 ·PLoS ONE ·Rocío Montes de, Christopher J. Shoemaker, Marjan Guček, Robert N. Cole, Katherine L. Wilson	83
16	Binding of Barrier to Autointegration Factor (BAF) to Histone H3 and Selected Linker Histones Including H1.1 2005 ·Journal of Biological Chemistry ·Rocío Montes de, KK Lee, Katherine L. Wilson	89
17	Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours breakdown → 2003 ·Nature ·David M. Berman, Sunil Karhadkar, Anirban Maitra, Rocío Montes de, Meg R. Gerstenblith, Kimberly J. Briggs, Antony R. Parker, Yutaka Shimada, James R. Eshleman, D. Neil Watkins, Philip A. Beachy	1019
18	A novel diagnostic screen for defects in the Fanconi anemia pathway 2002 ·Blood ·Akiko Shimamura, Rocío Montes de, John L. Svenson, (unknown), Lisa A. Moreau, David G. Nathan, Alan D. D’Andrea	83
19	Functional analysis of patient-derived mutations in the Fanconi anemia gene, FANCG/XRCC9 2001 ·Experimental Hematology ·Koji Nakanishi, Anna Moran, (unknown), Yanan Kuang, Edward Fox, Danielle Garneau, Rocío Montes de, Markus Grompe, Alan D. D’Andrea	21
20	Targeted disruption of the murine Fanconi anemia gene,Fancg/Xrcc9 2001 ·Blood ·Yi Yang, Yanan Kuang, Rocío Montes de, (unknown), Lisa A. Moreau, Naifang Lu, Brian Seed, Alan D. D’Andrea	105

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact